Stocks Considered 'Quality' by This Money Manager: Microsoft, Broadcom, Lilly, and More
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Should l Buy UNH?
Source: Barron's
Market Performance of Quality Stocks: The current market has not favored quality stocks, which are typically blue-chip companies with stable profits and low debt.
GMO's Outperformance: Funds managed by Tom Hancock at GMO have consistently outperformed both other quality portfolios and the broader market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNH
Wall Street analysts forecast UNH stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 289.210
Low
330.00
Averages
397.82
High
444.00
Current: 289.210
Low
330.00
Averages
397.82
High
444.00
About UNH
UnitedHealth Group Incorporated is a healthcare and well-being company. Its segments include Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State. Optum Health offers comprehensive and patient-centered care, addressing the physical, mental, social, and financial well-being. Optum Health delivers primary, specialty and surgical care; helps patients and providers navigate and address complex, chronic and behavioral health needs. Optum Insight connects the healthcare system with services, analytics and platforms that make clinical, administrative and financial processes simpler and more efficient for all participants in the healthcare system. Optum Rx offers a range of pharmacy care services through retail pharmacies, through home delivery, specialty and community health pharmacies and the provision of in-home and community-based infusion services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UnitedHealth Group Faces Significant Challenges Amid Rising Costs
- Rising Medical Care Ratio: UnitedHealth Group's medical care ratio reached 89.1% in 2025, up from 85.5% in 2024, indicating increasing pressure on the company's ability to manage medical expenses, which could adversely affect profitability.
- Significant Stock Decline: Over the past 12 months, UnitedHealth's stock has fallen by 37%, dropping from a 52-week high of $606 to around $293, reflecting market concerns about its future growth amid rising costs and billing investigations.
- Investor Confidence Eroding: Although the company offers a 3% above-average dividend yield, the uncertainty surrounding its business prospects has weakened investor confidence in the dividend, potentially leading to capital outflows and further stock price declines.
- Uncertain Future Growth: The future growth of UnitedHealth Group hinges on its ability to effectively reduce the medical care ratio; without significant improvement, investor skepticism regarding its profit growth potential may increase.
See More
UnitedHealth Plans to Sell Securities Amid Revenue Decline
- Securities Sale Plan: UnitedHealth (UNH) announced plans to sell a range of securities through a 'shelf' process, including debt, preferred stock, and common stock, which is expected to significantly impact its financing structure.
- Clear Use of Proceeds: The company stated that the proceeds from the offerings will be used for debt refinancing, stock buybacks, acquisitions, and other general corporate purposes, demonstrating a proactive approach to financial management.
- Revenue Decline Outlook: UnitedHealth projects its first annual revenue decline in decades, with cash and cash equivalents at $24.4 billion as of December 31, 2025, indicating a ~4% year-over-year drop, reflecting challenges in the market environment.
- Negative Market Reaction: Following four consecutive sessions of gains, UnitedHealth's stock slipped approximately 2% in premarket trading, indicating investor concerns regarding the company's future financial health.
See More
Eli Lilly Launches New Program to Enhance Obesity Drug Coverage
- Program Launch: Eli Lilly has introduced the 'Employer Connect' platform aimed at helping more employers cover obesity drugs, addressing a major barrier to patient access and expected to enhance employee drug accessibility.
- Price Transparency: Through this platform, employers can purchase a multi-dose form of Zepbound at a net discounted price of $449 per month, avoiding traditional rebate models, thereby providing clearer visibility on drug pricing for employers.
- Flexible Benefits Design: Employers can choose from 15 different third-party administrators to design benefits tailored to their budget and workforce needs, offering comprehensive obesity management services including telehealth, nutrition, and lifestyle support.
- Government Insurance Coverage: Under landmark deals with President Trump, Medicare will cover obesity drugs for the first time, which is expected to further expand drug accessibility and benefit more patients.
See More
Rising Health Insurance Costs Drag Wage Growth by 20%
- Wage Growth Constraints: The Federal Reserve Bank of New York estimated that rising employee health insurance costs, driven by GLP-1 obesity drugs and other factors, dragged wage growth down by as much as 20% last year, significantly impacting corporate compensation strategies.
- Projected Wage Increases: The research indicated that had health insurance costs not risen, businesses could have offered an average wage increase of approximately 4.7% in 2025, while the actual average wage increase was only 3.8%, highlighting the direct impact of cost pressures on wage policies.
- Rising Insurance Costs: The Kaiser Family Foundation estimated a 6% rise in health insurance costs for 2025, with the Fed survey confirming a 13% increase, reflecting the pressure of soaring healthcare expenditures on corporate operations.
- Corporate Response Strategies: Although not all firms provide health insurance, the study suggests that rising costs are increasing cost pressures for some businesses, thereby limiting wage growth for many workers and affecting overall economic vitality.
See More
Surge in Options Volume for UnitedHealth Group and Cheniere Energy
- UnitedHealth Options Activity: Today, UnitedHealth Group (UNH) options volume reached 49,795 contracts, equivalent to approximately 5 million shares, representing 53.4% of its average daily trading volume over the past month, indicating strong investor interest in the stock.
- High Volume Insights: Within UNH, the $300 strike call option has seen particularly high activity, with 6,540 contracts traded today, representing about 654,000 shares, reflecting market expectations for future price increases.
- Cheniere Energy Options Dynamics: Concurrently, Cheniere Energy (LNG) options also showed robust activity, with a volume of 9,939 contracts, equivalent to approximately 993,900 shares, also accounting for 53.4% of its average daily trading volume over the past month, highlighting market attention on the company.
- Put Option Trading: For LNG, the $240 strike put option has recorded a trading volume of 2,087 contracts, representing about 208,700 shares, indicating a cautious stance among investors regarding potential future price declines.
See More
UnitedHealth Group Stock Faces Significant Decline Amid Rising Costs
- Stock Decline: UnitedHealth Group's stock has fallen by 37% over the past year, dropping from a 52-week high of $606 to around $293, indicating market concerns about its future profitability.
- Rising Medical Care Ratio: The medical care ratio reached 89.1% in 2025, up from 85.5% in 2024, highlighting the company's challenges in controlling costs, which could impact its profit growth outlook.
- Investigations Impact: The company is facing investigations into its billing practices, which may negatively affect future growth and increase uncertainty for investors, putting pressure on the stock price.
- Dividend Attractiveness Declining: Although the stock offers a 3% dividend yield, investor confidence in the dividend may wane if the underlying business performance falters, prompting a more cautious investment approach.
See More
UnitedHealth Group Faces Significant Challenges Amid Rising Costs
- Rising Medical Care Ratio: UnitedHealth Group's medical care ratio reached 89.1% in 2025, up from 85.5% in 2024, indicating increasing pressure on the company's ability to manage medical expenses, which could adversely affect profitability.
- Significant Stock Decline: Over the past 12 months, UnitedHealth's stock has fallen by 37%, dropping from a 52-week high of $606 to around $293, reflecting market concerns about its future growth amid rising costs and billing investigations.
- Investor Confidence Eroding: Although the company offers a 3% above-average dividend yield, the uncertainty surrounding its business prospects has weakened investor confidence in the dividend, potentially leading to capital outflows and further stock price declines.
- Uncertain Future Growth: The future growth of UnitedHealth Group hinges on its ability to effectively reduce the medical care ratio; without significant improvement, investor skepticism regarding its profit growth potential may increase.
See More
UnitedHealth Plans to Sell Securities Amid Revenue Decline
- Securities Sale Plan: UnitedHealth (UNH) announced plans to sell a range of securities through a 'shelf' process, including debt, preferred stock, and common stock, which is expected to significantly impact its financing structure.
- Clear Use of Proceeds: The company stated that the proceeds from the offerings will be used for debt refinancing, stock buybacks, acquisitions, and other general corporate purposes, demonstrating a proactive approach to financial management.
- Revenue Decline Outlook: UnitedHealth projects its first annual revenue decline in decades, with cash and cash equivalents at $24.4 billion as of December 31, 2025, indicating a ~4% year-over-year drop, reflecting challenges in the market environment.
- Negative Market Reaction: Following four consecutive sessions of gains, UnitedHealth's stock slipped approximately 2% in premarket trading, indicating investor concerns regarding the company's future financial health.
See More
Eli Lilly Launches New Program to Enhance Obesity Drug Coverage
- Program Launch: Eli Lilly has introduced the 'Employer Connect' platform aimed at helping more employers cover obesity drugs, addressing a major barrier to patient access and expected to enhance employee drug accessibility.
- Price Transparency: Through this platform, employers can purchase a multi-dose form of Zepbound at a net discounted price of $449 per month, avoiding traditional rebate models, thereby providing clearer visibility on drug pricing for employers.
- Flexible Benefits Design: Employers can choose from 15 different third-party administrators to design benefits tailored to their budget and workforce needs, offering comprehensive obesity management services including telehealth, nutrition, and lifestyle support.
- Government Insurance Coverage: Under landmark deals with President Trump, Medicare will cover obesity drugs for the first time, which is expected to further expand drug accessibility and benefit more patients.
See More
Rising Health Insurance Costs Drag Wage Growth by 20%
- Wage Growth Constraints: The Federal Reserve Bank of New York estimated that rising employee health insurance costs, driven by GLP-1 obesity drugs and other factors, dragged wage growth down by as much as 20% last year, significantly impacting corporate compensation strategies.
- Projected Wage Increases: The research indicated that had health insurance costs not risen, businesses could have offered an average wage increase of approximately 4.7% in 2025, while the actual average wage increase was only 3.8%, highlighting the direct impact of cost pressures on wage policies.
- Rising Insurance Costs: The Kaiser Family Foundation estimated a 6% rise in health insurance costs for 2025, with the Fed survey confirming a 13% increase, reflecting the pressure of soaring healthcare expenditures on corporate operations.
- Corporate Response Strategies: Although not all firms provide health insurance, the study suggests that rising costs are increasing cost pressures for some businesses, thereby limiting wage growth for many workers and affecting overall economic vitality.
See More
Surge in Options Volume for UnitedHealth Group and Cheniere Energy
- UnitedHealth Options Activity: Today, UnitedHealth Group (UNH) options volume reached 49,795 contracts, equivalent to approximately 5 million shares, representing 53.4% of its average daily trading volume over the past month, indicating strong investor interest in the stock.
- High Volume Insights: Within UNH, the $300 strike call option has seen particularly high activity, with 6,540 contracts traded today, representing about 654,000 shares, reflecting market expectations for future price increases.
- Cheniere Energy Options Dynamics: Concurrently, Cheniere Energy (LNG) options also showed robust activity, with a volume of 9,939 contracts, equivalent to approximately 993,900 shares, also accounting for 53.4% of its average daily trading volume over the past month, highlighting market attention on the company.
- Put Option Trading: For LNG, the $240 strike put option has recorded a trading volume of 2,087 contracts, representing about 208,700 shares, indicating a cautious stance among investors regarding potential future price declines.
See More
UnitedHealth Group Stock Faces Significant Decline Amid Rising Costs
- Stock Decline: UnitedHealth Group's stock has fallen by 37% over the past year, dropping from a 52-week high of $606 to around $293, indicating market concerns about its future profitability.
- Rising Medical Care Ratio: The medical care ratio reached 89.1% in 2025, up from 85.5% in 2024, highlighting the company's challenges in controlling costs, which could impact its profit growth outlook.
- Investigations Impact: The company is facing investigations into its billing practices, which may negatively affect future growth and increase uncertainty for investors, putting pressure on the stock price.
- Dividend Attractiveness Declining: Although the stock offers a 3% dividend yield, investor confidence in the dividend may wane if the underlying business performance falters, prompting a more cautious investment approach.
See More
